KKD Healthcare Analytics | TalkMarkets | Page 1

KKD Healthcare Analytics

Healthcare Expert With 30 Years Experience
Contributor's Links: Dr KKD Healthcare Stock Tips

KKD Healthcare Analytics is a niche healthcare investment advisory service. Our goal is to channel our medical knowledge and long track record as a private investor into a website that will be the ultimate go-to place for knowledge and information about biotech ...more

Following: 17 Followers: 2328

Articles

Latest Posts
1 to 16 of 67 Posts
1 2 3 ... 5 >>>
Biotech Digest – XENT Gets FDA Approval, AGN Announces Acquisition, IONS Licenses Product
Tuesday, December 12, 2017 10:26 AM EDT
Intersect ENT Inc. reported the FDA approval for its SINUVA implant, designed to be used for treating recurrent nasal polyps in patients who have had previous ethmoid sinus surgery.
In this article: AGN, MRK, SNY, REGN, RPRX, XENT, IONS, TYHT
Read
Biotech Digest – KTOV Buys Stake, JNJ Reports Positive Results, NVS Receives CE Mark
Monday, October 9, 2017 8:52 AM EDT
Kitov Pharmaceuticals announced that it has acquired an additional 27% stake in privately held TyrNovo, a developer of small molecule oncology drugs.
In this article: KTOV, JNJ, NVS, ABEO, FLXN, IART, BABY, TRPX, CTLT
Read
Biotech Digest – INSM Reports Positive Data, MRK Gets EC Approval, LCI Receives FDA Approval
Tuesday, September 5, 2017 11:32 AM EDT
Oramed Pharmaceuticals reported the successful conclusion of its meeting with the FDA with regard to its drug candidate ORMD-0801. Insmed (INSM) stock jumped over 100 percent in the pre-market session.
In this article: CYH, MRK, TFX, LCI, ORMP, ALXN, APRI, BCRX, ISRG, INSM, BPMC, IOVA, APOP, ADVM
Read
Biotech Digest – IMDZ Reports Data, JNJ Terminates Collaboration
Friday, September 1, 2017 11:46 AM EDT
Immune Design announced interim top line data from a Phase 2 clinical trial assessing the combination of its CMB305 and Roche's Tecentriq (atezolizumab) compared to Tecentriq alone in 88 soft tissue sarcoma patients.
In this article: BKD, CNC, COO, CRL, JNJ, AMGN, CNMD, CMD, ADMS, IMDZ, MGNX, FWP, DXTR, IOVA, APVO
Read
Biotech Digest – URGN Receives Fast Track Designation, MDVX Receives Australian Approval, AZN Inks A New Deal
Wednesday, August 30, 2017 12:45 PM EDT
UroGen Pharma announced that the FDA has designated its MitoGel for Fast Track review for the treatment of patients with low-grade upper urinary tract urothelial carcinoma. AstraZeneca inked a new deal with Takeda Pharmaceutical.
In this article: AZN, RNN, SGEN, ABEO, TRHC, URGN, MDVX, MBRX
Read
Biotech Digest – GMED Receives Clearance, BIOC Inks New Collaboration, PFE Receives Approval
Friday, August 18, 2017 2:03 PM EDT
Globus Medical Inc. stock perked up as the company announced receiving the 510 (k) clearance from the FDA for Excelsius GPS. AstraZeneca announced receiving the FDA approval for its Lynparzaa. Pfizer has FDA approval for its Besponsa.
In this article: AZN, HUM, OPK, PFE, BIOC, FLDM, OMER, AMGN, MYGN, TTPH, GMED, HRTX, IOVA
Read
Biotech Digest – SGMO Announces Strong Quarterly Numbers, APEN Receives FDA Alert, CELG Modifies Collaboration
Friday, August 11, 2017 10:12 AM EDT
Sangamo Therapeutics shot up as the company announced better than expected quarterly numbers. Celgene announced modifying its collaboration with Sutro. Aethlon Medical reported that its net loss for the June 2017 quarter was $1.8 million.
In this article: AEMD, SGMO, CELG, AGTC, SPHS, GLPG, APEN
Read
Biotech Digest – CLRB Reports Positive Results, TNDM Receives New Patent, DERM Inks New Deal
Wednesday, August 9, 2017 10:13 AM EDT
Cellectar Biosciences stock shot up as the company announced achieving overall survival of 22.5 months to date after a single dose infusion of 12.5mCi/m2 in patients with multiple myeloma.
In this article: AET, AGN, BDX, JNJ, SNY, PLX, ACRX, ANTH, TNDM, AMRN, DERM, AKBA, AVXS, CLRB, ZBH
Read
Biotech Digest – FMI Inks New Deal, SGMI Gets Fast Track Designation, ANTM Files A Suit
Friday, July 14, 2017 10:00 AM EDT
What's new in the health care sector?
In this article: JNJ, TDY, HALO, SGMO, MYL, VRTX, FMI, ANTM, INSY
Read
Premarket Biotech Digest – CELG Inks New Deal, LLY Gets Favorable Ruling, ALR Modifies Deal
Monday, July 10, 2017 10:21 AM EDT
Celgene Corporation announced that it has agreed to acquire a stake in BeiGene. The deal has valued BeiGene stock at $4.58 apiece.
In this article: ALR, LLY, TNXP, BIIB, CELG, ITEK, CAPR, ENTL
Read
Anika Therapeutics Offers A Long-Term Growth Opportunity With Robust Pipeline
Wednesday, July 5, 2017 10:43 AM EDT
Anika Therapeutics has relatively mild risk profile. The company has established products in the market while its drug candidates have high probability of receiving the FDA approval as well as of performing well in the market.
In this article: ANIK
Read
Premarket Biotech Digest – PFE Receives EU Approval, ALKS Announces Positive Results, SRNE Receives FDA Approval
Friday, June 30, 2017 9:30 AM EDT
Pfizer Inc. announced receiving the European Commission’s approval for Besponsa treatment for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
In this article: MYOV, PFE, ALKS, SRNE, EIGR, WBA, LH, CTMX
Read
Pacific Biosciences Looks Promising As It Targets Low Competition Plant Genome Segment
Thursday, June 29, 2017 9:51 AM EDT
Pacific Biosciences has taken several remedial steps to ensure that Sequel systems gain wider approval in the market. These steps included designing software and chemical updates for the systems.
In this article: PACB
Read
Premarket Biotech Digest – DMPI Receives Approval, PFE Slapped From FDA
Friday, June 23, 2017 9:31 AM EDT
DelMar Pharmaceuticals announced that it has received Institutional Review Board approval to conduct a Phase 3 clinical trial. Pfizer received a setback from the FDA. Roche announced receiving the FDA approval .
In this article: PFE, RHHBY, TROV, QGEN, DMPI, IONS, VTGN, PRTO
Read
Corbus Moves Lead Candidate To Phase 3 Study, Offers Good Investment Deal
Thursday, June 22, 2017 9:33 AM EDT
Corbus has several catalysts coming up as it progresses with the testing of its lead drug candidate for different indications. Its earliest upcoming catalyst is in the fourth quarter.
In this article: CRBP
Read
Axsome Looks Good On Multiple Catalysts: Fast Track Designation Eases Liquidity Concerns
Tuesday, June 20, 2017 11:27 AM EDT
Axsome Therapeutics Inc. (AXSM) has multiple catalysts coming up in the near future as it has two main drug candidates under Phase 3 testing for multiple conditions. The stock has shown strength as it gained over 12 percent in the past one month.
In this article: AXSM
Read
1 to 16 of 67 Posts
1 2 3 ... 5 >>>